Sunitinib in Treatment of Advanced Non-Small Cell Lung Cancer after Failure of Multiregimens of Chemotherapy and Egfr-Tki

X. Liu,W. Wang,J. Li,C. Tang,F. Yu

DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.e18139

IF: 45.3

2010-01-01

Journal of Clinical Oncology

Abstract:e18139 Background: As no standard treatment for advanced NSCLC previously treated with both multiregimens of chemotherapy and EGFR-TKI was available, the study was to observe safety and efficacy of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, in treatment of these patients. Methods: 13 patients with advanced NSCLC received oral doses of 25-50 mg/day sunitinib on schedule 4/2 (4 weeks on treatment followed by 2 weeks of off treatment). Safety and tolerability was evaluated once a cycle. Patients with stable disease were treated until occurrence of disease progression or unacceptable adverse events. Results: There were 6 males and 7 females in the 13 patients with evaluable efficacy and adverse events (AEs) of sunitinib, and their age ranged 42∼69 years (median age 58 years). 12 were adenocarcinoma and only 1 bronchioloalveola carcinoma (BAC). There were 7, 5 and 1 patient(s) of PS1, PS2 and PS3(53.8%, 38.5% and 7.7%), respectively. Sunitinib was received as the fourth-line treatment or above (range: fourth-line ∼ ninth-line; median: sixth-line). Median duration of sunitinib treatment was 1.5 cycles (1- 8 cycles). No complete response (CR) was observed, partial response (PR) was seen in 3 patients (23.1%) with response time of 5, 10 and 12 months, respectively. Stable disease (SD) in 6 patients (46.2%) and progressive disease (PD) in 4 patients (30.8%). Common AEs included fatigue (69.2%), anorexia (69.2%), nausea (46.2%), skin pigmentation disorder (38.5%), hand-foot syndrome (30.1%), stomatitis (23.1%), hypertension (23.1%), peripheral edema (15.4 %), pleural effusion (15.4%) and diarrhea (15.4%), etc, most of which being grade 1∼2, with exceptions of grade 3∼4 AEs of dysgeusia (1 patient), hypertension (1 patient), anemia (1 patient), thrombocytopenia (1 patient) and skin ulceration at prior irradiated site (1 patient). All observed laboratory abnormalities, including thyroid dysfunction (23.1%), elevated ALT and/or AST (15.4%), abnormal EKG (1 patient), seemed mild. Conclusions: Advanced NSCLC patients previously treated with multiregimens of chemotherapy and EGFR-TKI may still benefit from Sunitinib treatment with tolerable AEs. No significant financial relationships to disclose.